U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2P.3Zn
Molecular Weight 258.175
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC PHOSPHIDE

SMILES

[P-3].[P-3].[Zn++].[Zn++].[Zn++]

InChI

InChIKey=IGSZOEHCOKSBEI-UHFFFAOYSA-N
InChI=1S/2P.3Zn/q2*-3;3*+2

HIDE SMILES / InChI

Molecular Formula HP
Molecular Weight 31.9817
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
2002 Mar 1
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].
2005
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and represented 40% of the recommended daily allowance of a male adult human. This dose was administered in water solution at a final volume of 1 mL per rat.
Route of Administration: Oral
In Vitro Use Guide
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:07:45 UTC 2023
Edited
by admin
on Wed Jul 05 23:07:45 UTC 2023
Record UNII
813396S1PC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC PHOSPHIDE
HSDB   ISO   MI   WHO-DD  
Common Name English
ZINC PHOSPHIDE [ISO]
Common Name English
Zinc phosphide [WHO-DD]
Common Name English
ZINC PHOSPHIDE [HSDB]
Common Name English
ZINCUM PHOSPHORATUM [HPUS]
Common Name English
TRIZINC DIPHOSPHIDE
Common Name English
ZINC PHOSPHIDE (ZN(SUB 3)P(SUB 2))
Common Name English
ZINCUM PHOSPHORATUM
HPUS  
Common Name English
ZINC PHOSPHIDE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C737
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
Code System Code Type Description
MESH
C009701
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
EPA CompTox
DTXSID1024386
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
ECHA (EC/EINECS)
215-244-5
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
RXCUI
1594583
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C77382
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
MERCK INDEX
M11622
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY Merck Index
PUBCHEM
25113606
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
HSDB
1059
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
WIKIPEDIA
ZINC PHOSPHIDE
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
FDA UNII
813396S1PC
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
ALANWOOD
zinc phosphide
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
DAILYMED
813396S1PC
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
CAS
1314-84-7
Created by admin on Wed Jul 05 23:07:45 UTC 2023 , Edited by admin on Wed Jul 05 23:07:45 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE